As of 2025-09-17, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (2.21) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.83 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -177.9%.
The range of the Relative Valuation is (2.01) - (2.70) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 19.6x | 14.8x |
| Forward P/E multiples | 14.6x - 23.5x | 17.2x |
| Fair Price | (2.01) - (2.70) | (2.21) |
| Upside | -170.9% - -195.4% | -177.9% |
| Date | P/E |
| 2025-09-12 | -21.44 |
| 2025-09-11 | -21.73 |
| 2025-09-10 | -21.29 |
| 2025-09-09 | -21.80 |
| 2025-09-08 | -22.75 |
| 2025-09-05 | -21.51 |
| 2025-09-04 | -21.95 |
| 2025-09-03 | -22.67 |
| 2025-09-02 | -22.60 |
| 2025-08-29 | -22.82 |
| 2025-08-28 | -22.75 |
| 2025-08-27 | -21.88 |
| 2025-08-26 | -22.46 |
| 2025-08-25 | -22.02 |
| 2025-08-22 | -23.18 |
| 2025-08-21 | -23.18 |
| 2025-08-20 | -22.67 |
| 2025-08-19 | -22.09 |
| 2025-08-18 | -22.60 |
| 2025-08-15 | -23.62 |
| 2025-08-14 | -23.91 |
| 2025-08-13 | -23.98 |
| 2025-08-12 | -24.13 |
| 2025-08-11 | -24.35 |
| 2025-08-08 | -24.86 |
| 2025-08-07 | -21.88 |
| 2025-08-06 | -27.51 |
| 2025-08-05 | -27.04 |
| 2025-08-04 | -27.33 |
| 2025-08-01 | -27.04 |
| 2025-07-31 | -26.78 |
| 2025-07-30 | -26.60 |
| 2025-07-29 | -25.51 |
| 2025-07-28 | -26.09 |
| 2025-07-25 | -25.87 |
| 2025-07-24 | -27.91 |
| 2025-07-23 | -29.14 |
| 2025-07-22 | -27.98 |
| 2025-07-21 | -27.91 |
| 2025-07-18 | -28.05 |
| 2025-07-17 | -28.20 |
| 2025-07-16 | -28.34 |
| 2025-07-15 | -28.20 |
| 2025-07-14 | -28.85 |
| 2025-07-11 | -28.56 |
| 2025-07-10 | -28.92 |
| 2025-07-09 | -29.00 |
| 2025-07-08 | -26.96 |
| 2025-07-07 | -26.38 |
| 2025-07-03 | -26.31 |